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Abstract
As an efficient drug for alveolar echinococcosis (AE) is still not available, new chemo-
therapy targets are necessary. The mitochondrial respiratory chain may be a good drug 
candidate because parasite respiratory chains are quite different from those of mamma-
lian hosts. For example, Ascaris suum possesses an NADH‐fumarate reductase system 
(fumarate respiration) that is highly adapted to anaerobic environments such as the 
small intestine. It is composed of mitochondrial complex I (NADH‐ubiquinone reduc-
tase), complex II (succinate‐ubiquinone reductase), and rhodoquinone. We previously 
demonstrated that fumarate respiration is also essential in E. multilocularis. Quinazoline, 
a complex I inhibitor, inhibited growth of E. multilocularis larvae in vitro. These results 
indicate that fumarate respiration could be a target for E. multilocularis therapy. In the 
current chapter, we focused on complex II, which is another component of this system, 
because quinazoline exhibited strong toxicity to mammalian mitochondria. We evaluated 
the molecular and biochemical characterization of E. multilocularis complex II as a poten-
tial drug target. In addition, we found that ascofuranone, a trypanosome cyanide‐insensi-
tive alternative oxidase inhibitor, inhibited E. multilocularis complex II at the nanomolar 
order. Our findings demonstrate the potential development of targeted therapy against 
Echinococcus complex II.
Keywords: Echinococcus multilocularis, drug discovery, fumarate respiration, 
mitochondrial complex II, ascofuranone
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1. Treatment and prevention of echinococcosis
1.1. Treatment of alveolar echinococcosis
Echinococcosis is a zoonosis caused by adult or larval stage Echinococcus, tiny cestode para-
sites in the family Taeniidae. The two major species of medical and public health importance 
are Echinococcus granulosus and E. multilocularis, which cause cystic echinococcosis (CE) and 
alveolar echinococcosis (AE), respectively. This chapter describes the main objective of AE 
therapy, which is more difficult to treat than CE. Treatment for CE generally includes alben-
dazole, surgery, and puncture, aspiration, injection, and reaspiration (PAIR) therapy, or a 
combination thereof, according to the World Health Organization diagnostic classification 
[1, 2]. The cure rate of PAIR therapy is especially high, at 97% for cysts exceeding 5 cm in 
size [3, 4]. However, PAIR therapy has not been adopted for AE. In surgical treatment of 
AE, radical resection is required for hepatic lesions. Conservative and palliative surgery are 
not recommended since they have no advantage over chemotherapy [5]. Liver transplanta-
tion is a therapeutic option for patients unsuitable for radical surgery with hepatic failure. 
Extrahepatic spread of AE in liver transplant recipients may lead to a risk of relapse due 
to the use of immunosuppressive agents after surgery [6, 7]. In addition, it is not easy to 
perform liver transplantation in developing countries without advanced medical equipment 
and high health care costs. As radical surgery for advanced AE is more difficult than that 
for CE, chemotherapy plays a key role in treatment of AE. Albendazole, a benzimidazole 
anthelmintic, is primarily used in chemotherapy for AE. The 15‐year survival of albendazole 
treatment is 53–80% in patients not treated by surgery, according to the condition of cysts 
[3, 8, 9]. Furthermore, two‐thirds of patients experienced one or more side effects of albenda-
zole, and the development of major side effects led to permanent discontinuation of alben-
dazole in 3.8% of patients [10]. Praziquantel, which is expected to have a synergistic effect 
with albendazole, is insufficient for AE [11]. Although in vivo studies have evaluated the 
effectiveness of a calcium channel blocker, thymol, and novel compounds are reported as 
new chemotherapy, they have only a limited effect on AE [12–14]. A recent report revealed 
that nitazoxanide, an anticipated promising drug, had no effect on treatment of AE [15]. These 
findings emphasize the difficulty in developing an effective drug for AE. Additionally, there 
are no other treatment options for patients in whom albendazole chemotherapy failed and 
who have no indications for liver transplantation.
1.2. Current status of the development of a vaccine against echinococcosis
Vaccine targets for echinococcosis are either intermediate or definitive hosts or both. EG95 
was identified as a candidate vaccine antigen for intermediate hosts of E. granulosus in 1998 
[16, 17]. As intermediate hosts of CE are livestock, such as sheep, goat, and cattle, vaccination 
of intermediate hosts of CE would presumably lead to the reduction of economic loss and 
the effective control of CE in the life cycle. In a pilot field trial of the EG95 vaccine, vaccine 
introduction in a sheep farm led to a statistically significant reduction in the number and 
size of hydatid cysts compared to the control area where the vaccine was not applied. The 
prevalence of infection in the vaccinated area was reduced by 62% compared to the control 
area [18].
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The gene product of E. multilocularis, EM95, is homologous to EG95 [19]. Mice immunized 
with the EM95 recombinant protein following challenge infection showed a significantly 
decreased number of cysts compared with control mice [19]. Furthermore, EMY162 antigen, 
which is also homologous to EG95, was identified in 2007 [20, 21]. Several candidate vaccine 
antigens based on homology to EM95 or EMY162 were subsequently reported [22, 23]. In 
addition, a transmembrane protein, tetraspanin (TSP), was identified as the antigen protein 
of an AE vaccine [24]. Protective effects of recombinant TSP against AE have been reported 
[25, 26]. However, it is difficult to apply a vaccination strategy to wild mice, which are the 
main intermediate hosts of AE. Although human AE is a serious parasitic disease, there has 
been little progress on application of these vaccines to humans since safety standards are 
exceptionally high.
Development of a vaccine for the definitive host dog is important because such a vaccine 
might contribute to a considerable reduction of human CE and AE in endemic areas. However, 
no effective vaccine candidate has been identified despite various trials. Although some oral 
recombinant vaccines showed high levels of protection against E. granulosus in dogs [27–29], 
these reports have been criticized in terms of their statistical analyses [30]. However, mucosal 
immunization with a parasite surface antigen, with cholera toxin subunit B as a carrier mole-
cule, induced a protective response to E. multilocularis infection in dogs [31]. Immunized dogs 
infected five times with E. multilocularis remained capable of excluding adult worms after 
a 6‐month interval [32, 33]. These results suggest the potential effectiveness of the mucosal 
vaccine against E. multilocularis in definitive hosts.
2. Mitochondrial respiratory chain as a drug target
2.1. NADH‐fumarate reductase system (fumarate respiration)
Since the 1970s, when albendazole became available for clinical use, no new drugs for echi-
nococcosis have been identified, as mentioned above. As an efficient drug for AE is still not 
available, new chemotherapy targets are necessary [34, 35]. Our group has focused on the 
mitochondrial respiratory chain, namely the NADH‐fumarate reductase system, of para-
sites as a potential drug target. Parasitic helminthes possess an NADH‐fumarate reductase 
system that is highly adapted to anaerobic conditions [36, 37]. The parasitic nematode Ascaris. 
suum is a suitable model for biochemical studies of mitochondrial NADH‐fumarate reductase 
systems because the body sizes of adult worms are easy to manipulate. We previously 
reported that the NADH‐fumarate reductase system is a good target for the development of 
novel, selective anthelmintic compounds as modeled in A. suum [38, 39]. It is composed of 
complex I (NADH‐quinone reductase, NQR), complex II (quinol‐fumarate reductase, QFR), 
and a low‐potential electron mediator, rhodoquinone (RQ). Low‐potential RQ transfers 
the reducing equivalent of NADH via complex I to complex II, and succinate is ultimately 
produced by QFR activity of complex II. The merit of this system is ATP synthesis using the 
coupling site of complex I even in the absence of oxygen. QFR catalyzes the reduction of fuma-
rate to succinate, while SQR (succinate‐quinone reductase, used in mammalian systems) does 
the oxidation of succinate in the opposite direction (Figure 1). The NADH‐fumarate reductase 
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system is absent in mammalian mitochondria living in aerobic conditions. Therefore, this 
unique respiratory system is considered to be a promising chemotherapeutic target for the 
development of novel anthelmintics.
2.2. Mitochondrial complex II
Complex II is a member of the tricarboxylic acid (TCA) cycle and respiratory chain. SQR as 
complex II catalyzes the oxidation of succinate to fumarate in the TCA cycle and transfers the 
electron to ubiquinone in the respiratory chain. QFR as complex II catalyzes the reduction of 
fumarate to succinate, a reverse reaction of succinate dehydrogenase (SDH), in the respiratory 
chain of mitochondria from anaerobic animals such as A. suum as described above. Generally, 
complex II consists of four subunits. Flavoprotein (Fp) subunit contains flavin adenine dinu-
cleotide (FAD) as a prosthetic group and iron‐sulfur protein (Ip) subunit contains three iron‐
sulfur (Fe‐S) clusters [38]. The complex also contains large and small hydrophobic cytochrome 
b (CybL and CybS, respectively) subunits. The succinate‐binding site is located in the Fp sub-
unit, while the quinone‐binding site is formed by the other three subunits, Ip, CybL, and CybS.
2.3. E. multilocularis complex II as a novel drug target
Our group has focused on the biochemical properties of complex II and its potential as a drug 
target against helminth infections [40–42]. This concept could be expanded to Echinococcus 
Figure 1. A schematic representation of the NADH‐fumarate reductase system in adult A. suum, which catalyzes the 
last step of the phosphoenolpyruvate carboxykinase‐succinate pathway. The NADH‐fumarate reductase system is 
composed of complex I (NADH‐quinone reductase), low‐potential rhodoquinone (RQ), and complex II (quinol‐fumarate 
reductase, QFR). In this system, electrons from NADH are transferred to RQ by the NADH‐RQ reductase activity of 
mitochondrial complex I and then transferred to fumarate by the QFR activity of mitochondrial complex II through the 
quinone‐binding site. Anaerobic electron transfer in complex I couples with proton transport across the mitochondrial 
inner membrane to generate ATP. A. suum complex II is composed of four subunits: flavoprotein subunit (Fp), iron‐
sulfur protein subunit (Ip), and cytochrome b large and small subunits (CybL and CybS, respectively). 3[Fe‐S], iron‐
sulfur clusters; FAD, flavin adenine dinucleotide; and FMN, flavin mononucleotide.
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species, which belongs to parasitic platyhelminthes, distinct from nematodes. As expected, 
we found that the NADH‐fumarate reductase system played a dominant role in isolated mito-
chondria from larval E. multilocularis [36]. In addition, quinazoline, an inhibitor of complex 
I, exhibited antiechinococcal activity under in vitro culture conditions [36]. These findings 
suggest that the NADH‐fumarate reductase system is a potential therapeutic target in E. multi‐
locularis. However, it is difficult to synthesize quinazoline derivatives. In addition, quinazoline 
and its derivatives exhibited strong toxicity in mammalian cells. Therefore, we focused on 
mitochondrial complex II in the NADH‐fumarate reductase system as a drug target. Flutolanil 
and atpenin A5 are known effective inhibitors of the quinone‐binding site of A. suum complex II 
[42, 43]. Elucidation of crystal structures of A. suum complex II in the presence of flutolanil 
provided useful information for the structure‐based design of a more effective inhibitor 
[39, 44]. As a crystallographic analysis of Echinococcus complex II is challenging, we conducted 
comparative analyses of E. multilocularis with other parasites and host enzymes.
We cloned cDNA of complex II and assembly factors of E. multilocularis and purified subunits 
of complex II from mitochondria by high resolution clear native electrophoresis (hrCNE) to 
determine N‐terminal amino acid sequences of mature subunits. In addition, we investigated 
the effects of several quinone‐binding site inhibitors on E. multilocularis complex II.
3. Characterization of E. multilocularis complex II as a drug target
3.1. Cloning and sequence analyses of the genes for four constitutive subunits and two 
assembly factors
Since genome project data from Brehm and colleagues were released in advance on their web-
site (Wellcome Trust Sanger Institute: http://www.sanger.ac.uk), we first identified complex 
II–related genes by BLAST search using human and other eukaryotic sequences as queries. A 
partial or full open reading frame (ORF) of four subunits composing mature complex II and 
two assembly factors were identified by TBLASTN search against expressed sequence tag 
(EST) or genomic contig and shotgun reads. Two isoforms were found for the Ip subunit, and 
the other subunits were encoded in a single gene each. Primers for the coding region of each 
gene were designed based on this information (Table 1). First, the coding region of the seven 
genes was amplified by gene‐specific PCR, and sequences were determined after insertion 
into a cloning vector. For rapid amplification of cDNA ends (RACE) of 5′ and 3′ ends, new 
primers were designed from the confirmed coding regions. Finally, cDNA sequences of sdha 
(Fp), sdhb1 (Ip1), sdhb2 (Ip2), sdhc (CybL), sdhd (CybS), sdhaf1, and sdhaf2 were determined 
(DDBJ accession numbers: AB699145–AB699151).
During 3′RACE of sdhaf1, we found that the first PCR yielded an exceptionally long amplified 
DNA fragment (ca. 1.4 kbp) compared to the ORF of sdhaf1 (288 bp). Interestingly, this frag-
ment contained another ORF homologous (27% of amino acid identity) to Tam41p in budding 
yeast (GenBank ID: NP_011560) [45], whose start codon overlapped the stop codon of sdhaf1. 
3′RACE was conducted again with gene‐specific primers complementary to the tam41 cod-
ing region, which is closer to the 3′‐terminal end of cDNA compared to the initial 3′RACE 
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Primer Sequences Experiment
Fp‐1 F 5′‐AGGCTCCCAAGGCTGTTATC‐3′ ORF
Fp‐2 R 5′‐GCAGACGTTCTGATCTAAAG‐3′ ORF & 5′RACE 1st
Fp‐3 F 5′‐GCTTGCGCCCTCGATATT‐3′ 3′RACE 1st
Fp‐4 F 5′‐GTCTCATATGGAACTCGGAC‐3′ 3′RACE 2nd
Fp‐5 R 5′‐CGGAGTGAGCGACCGTATAGAG‐3′ 5′RACE 2nd
Fp‐6 F 5′‐CAGTTTTCGTGCACCTTCATGG‐3′ ORF‐full
Fp‐7 R 5′‐CCTTGAACGATTAGTAGGAACGG‐3′ ORF‐full
Ip1‐1 F 5′‐TCCGTTCTCTGCTTTTCGAC‐3′ ORF & 3′RACE 1st
Ip1‐2 R 5′‐TCAGCATCTTCTTGATCTCACC‐3′ ORF
Ip1‐3 F 5′‐TCTGCGCTATTCCCAAAGAT‐3′ 3′RACE 2nd
Ip1‐4 R 5′‐GGAATAGCGCAGAGACAGGCCAGAC‐3′ 5′RACE 1st
Ip1‐5 R 5′‐GAGCGTCAAGCATCATGGGAC‐3′ 5′RACE 2nd
Ip1‐6 F 5′‐TCGCCAGGAGAATGAATTCC‐3′ ORF‐full
Ip1‐7 R 5′‐GTCACTTCGAACCGGTTCAG‐3′ ORF‐full
Ip2‐1 F 5′‐GATAACTTGCAAGCGTGC‐3′ 3′RACE 1st
Ip2‐2 F 5′‐GTCCGGCTACATTGATACAC‐3′ 3′RACE 2nd
Ip2‐3 R 5′‐AATTTTGGTGACTTTATTGCTCCTC‐3′ 5′RACE 1st
Ip2‐4 R 5′‐AATGTGAGGGTTGGGTCGCAT‐3′ 5′RACE 2nd
Ip2‐5 F 5′‐GTGGTGGGAACATGAATTGTGTTTG‐3′ ORF‐full
Ip2‐6 R 5′‐GAATGCATCACAATGCCAGGA‐3′ ORF‐full
CybL‐1 F 5′‐TTTTTGCGAACGTTCTGTTG‐3′ ORF & 3′RACE 1st
CybL‐2 R 5′‐CTTCCACAGGTCCGAACAC‐3′ ORF
CybL‐3 F 5′‐AAGGGCAGCACAAGTGAGG‐3′ 3′RACE 2nd
CybL‐4 R 5′‐CCATGGCGACACCAGTAGCACGG‐3′ 5′RACE 1st
CybL‐5 R 5′‐AATATGTGAGGCGACCACGGG‐3′ 5′RACE 2nd
CybL‐6 F 5′‐GCGCGGTTAGACATGTCG‐3′ ORF‐full
CybL‐7 R 5′‐GGCTAGCAACATCTAGCTCCTG‐3′ ORF‐full
CybS‐1 F 5′‐ATGTCTTTCGCGCTTTTGG‐3′ ORF
CybS‐2 R 5′‐TTTTGACGCCCTTAATAACACC‐3′ ORF, 5′RACE 1st & 2nd
CybS‐3 F 5′‐GCGAAGTTGGGGACAGCT‐3′ 3′RACE 2nd
CybS‐4 F 5′‐GGCTTCATTGGCAGGATGTC‐3′ ORF‐full
CybS‐5 R 5′‐CACTGCGTGCTCAAAGAGACC‐3′ ORF‐full
AF1‐1 F 5′‐ATGTCTCGCCCATATAGTCAACTTC‐3′ ORF & 3′RACE 1st
AF1‐2 R 5′‐TTAATCTTGTTTATGGGGAGGAAAAG‐3′ ORF & 5′RACE 1st
AF1‐3 F 5′‐GACAGGTTCTGAAGCTCTATAAGGA‐3′ 3′RACE 2nd
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experiment. The presence of this polycistronic mRNA was confirmed by PCR with primers 
that were complementary to the 5′ untranslated region (UTR) of sdhaf1 and 3′ UTR of tam41.
The number of amino acids of all determined proteins and their sequence identities with cor-
responding proteins in A. suum and humans are summarized in Table 2. The position from 
the first methionine (Met) of the N‐terminal sequences of the four subunits in mature complex 
II is also listed in parentheses next to these 10 amino acids’ sequences in Table 3. The two 
isoforms of Ip share the same sequence in this region. Two isoforms of Ip were reported in 
the parasitic nematode Haemonchus contortus [46]. Additionally, there are two isoforms of Fp, 
type I and II, in human complex II. It is speculated that complex II with type II Fp has a higher 
QFR activity and plays an important role in fumarate respiration in human mitochondria as 
the terminal oxidase of the system [38]. Isoforms of E. multilocularis Ip might be related to 
Primer Sequences Experiment
AF1‐4 F 5′‐ATATGGGGTCGTTGGTTATG‐3′ 3′RACE 1st
AF1‐5 F 5′‐AGTAGAGACGCCAATCACCACGA‐3′ 3′RACE2nd
AF1‐6 R 5′‐GACCTGCCTCAAGGTCTTCC‐3′ 5′RACE 2nd
AF1‐7 F 5′‐TTGATTATTAGCGCAATATAAGGTG‐3′ ORF‐full
AF1‐8 R 5′‐TTTTCTAAATGTTTTATTCAGGCAAA‐3′ ORF‐full
AF2‐1 F 5′‐ATGGTGCTGTCTCTTAATCGTTTGAC‐3′ ORF & 3′RACE 1st
AF2‐2 R 5′‐CTACACAGTGTGGGGGTGAATATTG‐3′ ORF & 5′RACE 1st
AF2‐3 F 5′‐TCTGTTGCGACAATGAGGAG‐3′ 3′RACE 2nd
AF2‐4 R 5′‐TCTGTTGCGACAATGAGGAG‐3′ 5′RACE 2nd
AF2‐5 F 5′‐ACTATTAAACTTTCTGCTTGGTTGCAT‐3′ ORF‐full
AF2‐6 R 5′‐GTTGTATATAATGCTGTAATTAACTAATAGGACAAC‐3′ ORF‐full
Table 1. Gene‐specific primers used in this chapter.
Identity of amino acid sequence (%)
Gene Product Amino acids A. suum Human
(adult)
sdha Fp 647 68 72
sdhb1 Ip1 282 58 62
sdhb2 Ip2 282 57 62
sdhc CybL 194 23 31
sdhd CybS 153 27 30
sdhaf1 SDHAF1 95 27 39
sdhaf2 SDHAF2 140 31 41
Table 2. Summary of cloning and translated amino acid sequence.
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changes in the respiration system, although the expression ratio of the two isoforms must be 
estimated during the life cycle.
3.2. Purification of E. multilocularis complex II by electrophoresis
As all the genes for mitochondrial complex II are chromosomally encoded and the N‐ terminal 
of each peptide is processed during mitochondrial localization, E. multilocularis complex II 
was partially purified and N‐terminal amino acid sequences of the subunits were deter-
mined. Mitochondrial samples solubilized and separated by hrCNE were further subjected 
to two‐dimensional SDS‐PAGE (see Section 5). Since first‐dimensional electrophoresis was 
conducted by hrCNE, the four subunits of complex II were expected to align under the SDH 
activity stained band (Figure 2A). Based on the apparent molecular weight, candidates of the 
four subunits were selected (indicated by black arrows): Fp (75 kDa), Ip (28 kDa), CybL (15 
kDa), and CybS (12 kDa) (Figure 2B). Bands corresponding to these subunits in protoscol-
eces (larval stage) and adult E. multilocularis were detected at the same positions. From the 
partially purified sample, four subunits could be stained by coomassie brilliant blue (CBB), 
and N‐terminal amino acid sequences were determined in 10 residues for those four bands 
(Table 3).
3.3. Inhibition of complex II by flutolanil, atpenin A5, and ascofuranone
We developed a method to separate E. multilocularis mitochondria to study its biochemical 
properties, including inhibitor screening. We constructed a quinone‐binding site inhibitor 
library since this site is considered a good target for antiparasitic drugs. The inhibitory effect 
of flutolanil, atpenin A5, and ascofuranone as representative inhibitors was subsequently 
analyzed.
Gene Product
Amino acid of premature protein (upper)
N‐terminal amino acid of mature protein ( positions*)
sdha Fp MAFLVRASFASFAARLGCLPTFAGASRHVSTVGKDYTI
VSTVGKDYTI (29–38)
sdhb1 Ip1 MNSVLCFSTRYACVIGQTARYASTGPVMKKF
ASTGPVMKKF (22–31)
sdhb2 Ip2 MNCVCSLSLRFEFLLIQTARYASTGPVMKKF
ASTGPVMKKF (22–31)
sdhc CybL MSVFANVLLRAHAAPFRGVAARNLSMALQPLLLRTAPVLSATKHYKGSTSEEVRL
KGSTSEEVRL (46–55)
sdhd CybS MSFALLASKHLIRRAAVSSFVSANACRTLVCTPNNKAKLGTAPQPV
AKLGTAPQPV (37–46)
*Positions of the N‐terminal 10 amino acids from the first Met in cDNA.
Table 3. N‐terminal amino acid.
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The 50% inhibitory concentration (IC50) values of flutolanil, atpenin A5, and ascofuranone for 
E. multilocularis QFR are shown in Table 4. The selectivity index was expressed with the IC50 of each inhibitor for porcine SQR. The IC50 and selectivity index of flutolanil for E. multilocularis QFR were 15 μM and 2.9, respectively (IC50 of porcine SQR was 44 μM), while the IC50 and selec-tivity index of flutolanil for A. suum QFR were 0.058 μM and 758, respectively [44]. The IC50 of atpenin A5 for porcine SQR (0.0036 μM) was lower than that for E. multilocularis (0.059 μM) 
and A. suum QFR (0.012 μM) [43]. Surprisingly, the IC50 and selectivity index of  ascofuranone, 
Figure 2. A SDH (succinate dehydrogenase) activity staining. Lane 1A: adult E. multilocularis and lane 2A: protoscoleces 
(PSC). CBB (Coomassie Brilliant Blue) staining. Lane 1B: adult E. multilocularis and lane 2B: PSC. Asterisks indicate 
complex II. Lane M: molecular weight markers. B. 2D SDS‐PAGE. Comparison of (1) PSC complex II, (2) adult complex 
II, (3) purified A. suum complex II, and (M) molecular weight markers. Candidates of four subunits were selected 
(indicated by black arrows), which correspond to flavoprotein (Fp, 75 kDa), iron‐sulfur cluster protein (Ip, 28 kDa), 
cytochrome b large subunit (CybL, 15 kDa), and cytochrome b small subunits (CybS, 12 kDa). Asterisks indicate PSC 
complex II subunits. PSC and adult complex II subunits demonstrated similar sizes.
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which was developed as an antitrypanosomal drug, for E. multilocularis QFR, were 0.85 μM and 
350, respectively, although the IC50 of ascofuranone for A. suum QFR was 10 μM.
4. Discussion
4.1. Features of E. multilocularis complex II
In this chapter, the molecular characterization of E. multilocularis complex II was performed, 
including complex II inhibitor screening.
The FAD prosthetic group of Fp is localized in the FAD‐binding domain by a covalent bond 
to histidine (His) and hydrogen bonds with highly conserved residues across amino acid 
sequences of complex II from various species [44, 47]. Fp in E. multilocularis has this conserved 
sequence, including the segment containing FAD‐bound His.
The Ip subunit generally contains three Fe‐S clusters coordinated by cysteine (Cys) resi-
dues [10]. The Ip subunit of E. multilocularis also has three well‐conserved Cys‐rich regions 
associated with the Fe‐S cluster. An unusual amino acid substitution was found in the Fe‐S 
cluster related to the Cys‐rich region. A comparison of this amino acid with the known 
crystal structure of complex II placed it spatially in the vicinity of the 4Fe‐4S center. We 
found two isoforms of E. multilocularis Ip (EmIp1 and EmIp2), which differ from each other 
by remarkable one amino acid residue. Leucine (Leu) 180 of EmIp1 and phenylalanine 
(Phe) 180 of EmIp2 are very rare substitutions in the second conserved Cys‐rich region 
among complex II. This position is primarily an alanine (Ala), and infrequently a gly-
cine, in bacterial or eukaryotic enzymes. Ala is generally located adjacent to the second 
conserved Cys in the second Cys‐rich region of Ip, interacting with the Fe‐S cluster in 
many species. E. multilocularis complex II functions as QFR with RQ as the electron donor. 
Interestingly, Rhodospirillum rubrum, a photosynthetic bacterium that we consider as a can-
didate expression host for E. multilocularis complex II, has a Phe at this position, similar to 
EmIp2. Because R. rubrum has RQ and ubiquinone as hydrophobic electron carriers in the 
cytoplasmic membrane, its complex II may function as QFR, utilizing RQ similar to E. mul‐
tilocularis. Cloning of sdhb (Ip) highlighted the features of E. multilocularis complex II. The 
role of this amino acid residue in the catalytic activity will be studied in future mutational 
analyses of E. multilocularis and R. rubrum complex II.
Inhibitor IC50 (μM) Selectivity index
E. multilocularis QFR A. suum QFR Porcine SQR Porcin IC50/E. 
multilocularis IC50
Flutolanil 15 ± 0.28 0.058* 44 2.9
Atpenin A5 0.059 ± 0.0063 0.012** 0.0036 0.061
Ascofuranone 0.85 ± 0.070 10 300 350
*Harada et al. Biochimica et Biophysica Acta. 2013;1827:658‐667.
**Miyadera et al. Proceedings of the National Academy of the Sciences USA. 2003;21:473‐477.
Table 4. The inhibitory effect of representative quinone‐binding site inhibitors.
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In our chapter, mitochondrial complex II of E. multilocularis was purified by preparative 
hrCNE, and N‐terminal amino acid sequences of all four subunits from mature enzymes were 
determined. The benefit of employing preparative hrCNE is that the loss of protein during the 
experiment is small since the condition is already fixed by analysis on a minigel. Purification 
starting with 2.6 mg of mitochondrial protein successfully yielded a sufficient amount of puri-
fied complex II for subsequent protein sequencing analysis.
4.2. Identification of sdhaf1 and sdhaf2
Functional expression of eukaryotic complex II in other organisms is difficult because 
complex II is a multi‐subunit enzyme, and many prosthetic groups, such as FAD, are asso-
ciated with this enzyme. In this condition, two important proteins, succinate dehydro-
genase assembly factor 1 (SDHAF1) and SDHAF2 (SDHAF2, or SDH5), involved in the 
synthesis of functional complex II were reported. Their gene products are not the com-
ponents of mature complex II [48–50]. SDHAF1 is suggested to play an essential role in 
complex II assembly. SDHAF2 may be required for the insertion of FAD cofactor into Fp. 
Coexpression of these genes with the four subunits present in mature complex II may be 
required for functional expression of eukaryotic complex II in heterologous expression 
systems such as bacteria.
Although sdhaf2 of A. suum and Caenorhabditis elegans was annotated, sdhaf1 has not been 
annotated in the EST database [https://www.ncbi.nlm.nih.gov/nucest] or WormBase [http://
www.wormbase.org]. Furthermore, the genome annotation of sdhaf1 has not been assigned 
in the draft genome sequence and transcriptome analysis of Echinococcus [51]. TBLASTN 
search using human and other eukaryotic sequences as queries in WormBase [http://www.
wormbase.org/tools/blast_blat] against the genome detected the sdhaf1 candidate region 
as an intron‐less structure on chromosome V, corresponding to positions 4710485–4710739 
(genomic position: 4710485–4710739). In the EST database, the corresponding sequence was 
found as an ORF before the start codon of cif‐1, an ortholog of human eukaryotic translation 
initiation factor 3, and ORF in several mRNA variants of cif‐1 (e.g., yk1259f02.5). However, 
cif‐1 itself is not related to complex II or Tam41P. BLASTP search in WormBase did not yield 
the sequence found in the genome and EST. Taken together, sdhaf1 found in C. elegans genome 
and its expression was observed, although not annotated. A homologous gene was also found 
in A. suum (GenBank ID: JI213553). After the first report of SDHAF1 and SDHAF2, several 
studies have reported SDHAF2 but not SDHAF1. Identification of the prokaryotic gene cor-
responding to sdhaf2, named sdhE in prokaryotes, suggests a common role of this gene for the 
assembly process of the complex II. However, sdhaf1 was not annotated as a protein coding 
gene in WormBase, which is one of the best organized and updated genes and protein data-
bases for C. elegans. Cloning of E. multilocularis sdhaf1 revealed polycistronic expression of 
this gene with downstream tam41. The same genome structure was conserved in Schistosoma 
mansoni, the first genomic reference for Platyhelminthes. A homologous ORF was identified 
in C. elegans EST database as a part of cif‐1 mRNA. Considering the small size of this gene 
(<300 bp) and the gene arrangement in E. multilocularis and S. mansoni, transcription in a 
polycistronic manner in C. elegans does not necessary indicate a correlation between sdhaf1 
and cif‐1. However, because of its small size and mRNA structure, this gene might have been 
overlooked in this organism.
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4.3. Inhibition of complex II by a quinone‐binding site inhibitor
An inhibitor of the mitochondrial respiratory chain, atovaquone, has been used as an antima-
larial agent [52]. Thus, it is reasonable to identify potent and specific inhibitors for the respi-
ratory chain of E. multilocularis. Flutolanil, a commercially available fungicide, specifically 
inhibits helminth complex II [42]. The IC50 and selectivity index of flutolanil for A. suum were 58 nM and 762, respectively. The flutolanil‐binding site is located at the RQ‐binding pocket, 
which is formed at the interface domain composed of three subunits, Ip, CybL, and CybS [39, 
44]. Moreover, CH‐π interaction between flutolanil isopropyl group and tryptophan69 (Trp) 
in CybL is one of the significant factors for the highly specific inhibitory effects of flutolanil 
against A. suum complex II [44]. Our finding that Trp69 is replaced with methionine (Met) in E. 
multilocularis and human (arrow A in Figure 3) likely explains why complex II activity in E. mul‐
tilocularis was not inhibited by flutolanil. In fact, Harada et al. reported that porcine complex II 
is resistant to flutolanil since Trp69 is replaced by Met in porcine CybL [44]. Furthermore, in E. 
multilocularis, a phenylalanine (Phe) is located four amino acids downstream of the Met (arrow 
B in Figure 3). This Phe is replaced with isoleucine in human. This information is useful for 
the design of selective inhibitors of E. multilocularis complex II because the Phe residue forms a 
strong interaction, such as CH‐π or cation‐π interaction, with the inhibitor [53, 54].
Interestingly, ascofuranone, which is a specific quinone‐binding site inhibitor of cyanide‐
insensitive trypanosome alternative oxidase in Trypanosoma brucei mitochondria [55, 56], 
inhibited E. multilocularis QRF at the nanomolar order. To our knowledge, this study is the 
first to demonstrate that ascofuranone acts as a complex II inhibitor. Furthermore, our pre-
liminary study showed ascofuranone has the ability to kill protoscoleces in culture within 
several days (data not shown). Our findings may aid in the development of new targeted 
therapy against Echinococcus complex II. We have synthesized more than 400 ascofuranone 
derivatives and will evaluate the structure‐activity relationship in in vitro and in vivo studies.
5. Experimental information
5.1. Isolation of E. multilocularis protoscoleces and preparation of enriched mitochondrial 
fractions
The Nemuro strain of E. multilocularis, which is maintained at biosafety level 3 in the Hok‐
kaido Institute of Public Health (Sapporo, Japan), was used in this study. The mitochondria 
Figure 3. A comparison of the amino acid sequence of cytochrome b large subunit (CybL) from E. multilocularis (E. m), 
human (Hum), and A. suum (A. s). The arrow A indicates that tryptophan at position 69 is replaced with methionine in 
E. multilocularis and human. The arrow B indicates the phenylalanine four amino acids downstream of the methionine at 
arrow A in E. multilocularis is changed to isoleucine in human.
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of protoscoleces were prepared as described previously [36]. To isolate protoscoleces, the 
mature larval parasites were minced with scissors, pushed through a metal mesh, and washed 
repeatedly with physiological saline. The isolated protoscolex sediment was suspended in 5 
volumes of mitochondrial preparation buffer (210 mM mannitol, 10 mM sucrose, 1 mM diso-
dium EDTA, and 50 mM Tris‐HCl [pH 7.5]), supplemented with 10 mM sodium malonate. 
The parasite materials were homogenized with a motor‐driven glass/glass homogenizer. The 
homogenate was diluted with the mitochondrial preparation buffer to 10 times the volume of 
the original protoscolex sediment and then centrifuged at 800 × g for 10 min to precipitate cell 
debris and nuclei. The supernatant was then centrifuged at 8000 × g for 10 min to obtain the 
mitochondrial pellet. The pellet was resuspended in mitochondrial preparation buffer (with-
out malonate) and centrifuged at 12,000 × g for 10 min. The enriched mitochondrial fraction 
was suspended in mitochondrial preparation buffer (without malonate) [36].
5.2. hrCNE and two‐dimensional SDS‐PAGE
Separation profile of complex II by hrCNE was analyzed and the condition for purification was 
optimized by isocratic acrylamide minigel. The mitochondrial membrane of E. multilocularis 
was suspended as 10 mg/mL protein in gel buffer (50 mM Tris‐HCl, pH 8.0). The membrane 
was solubilized by the addition of 50 mM Tris‐HCl (pH 8.0), 4% SML (sucrose monolaurate), 
40% (v/v) glycerol, and 2 mM sodium malonate on ice followed by centrifugation (200,000 × g, 
4°C, 30 min). The supernatant was mixed with 1/10 volume of loading dye (50% glycerol and 
0.1% Ponceau S), and 55 μL of the resulting solution was applied to the well. Anode buffer (20 
× running buffer) and cathode buffer (20 × running buffer, 0.02% n‐dodecyl‐β‐D‐maltoside, 
and 0.05% sodium deoxycholate) were used irrespective of the detergent for solubilization. 
Electrophoresis was performed in a cold room (4°C), starting with 100 and 250 V constant volt-
age for 1 h. The complex II band was visualized by GelCode Blue Safe Protein Stain (Thermo 
Scientific) or SDH activity staining. For activity staining, a gel strip was soaked in 10 mL of 5 
mM Tris‐HCl (pH 7.4) containing 25 mg of nitro blue tetrazolium, and then the reaction was 
started by the addition of 150 μL of 4 mg/mL phenazine methosulfate and 200 μL of 1 M sodium 
succinate. The complex II band was detected by activity staining and cut from the one‐dimen-
sional gel (CBB staining). The gel was equilibrated with SDS‐PAGE buffer and then loaded onto 
the two‐dimensional gel (4.5% acrylamide, 0.12% bisacrylamide, 0.25 M Tris‐HCl (pH 6.8), 0.4% 
sodium dodecyl sulfate, 0.05% ammonium persulfate, and N,N,N',N'‐tetramethylethylenedi-
amine). Protein spots were visualized by silver staining (2D‐Silver Stain‐II kit, Cosmo Bio).
5.3. Partial purification of complex II by preparative hrCNE
Prepforesis® (ATTO) was used for preparative hrCNE. Separation gel (8% acrylamide) 
was prepared in a 1.6‐cm diameter column at 2‐cm height, and sample gel (3% acrylamide) 
was layered at 1‐cm height. For solubilization, 2.6‐mg protein of E. multilocularis mitochon-
dria was precipitated, resuspended in 300 μL of solubilization buffer (10 mM Tris‐HCl, 0.5 
M 6‐aminohexanoic acid, 5% (v/v) glycerol, 2.5% digitonin, pH 8.0), and kept on ice for 1 h. 
The resulting suspension was centrifuged (200,000 × g, 10 min), and 3 μL of loading dye was 
added to the supernatant. The buffer system was the same as that of the minigel and kept at 
6°C by a circulator. Electrophoresis was performed at 10 mA. The volume of one fraction was 
approximately 650 μL and 50 fractions were collected.
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5.4. N‐terminal amino acid determination of complex II constitutive subunits
Complex II‐containing fractions from hrCNE were individually concentrated to approximately 
70 μL by Amicon Ultra‐4 Centrifugal Filter Units (molecular weight cutoff is 50,000). After 
rough estimation of the concentration and purity of complex II on SDS‐PAGE with silver stain-
ing, protein was precipitated with trichloroacetic acid. Briefly, 30 μL of water and 10 μL of 100% 
(w/v) trichloroacetic acid solution were added to 60 μL of concentrated fraction and then the 
mixture was incubated on ice for 15 min and sedimented (14,000 × g for 10 min). These samples 
were then subjected to 12.5% SDS‐PAGE, and proteins were transferred to an Immobilon‐P 
membrane (Millipore), followed by staining with CBB G‐250. Ten amino acid residues were 
determined with a Procise 494 cLC Protein Sequencing System (Applied Biosystems) at APRO 
Life Science Institute (Tokushima, Japan).
5.5. cDNA synthesis and cloning of complex II–related genes
Frozen mature larval parasites were pulverized with a mortar and pestle in liquid nitrogen, 
and total RNA was prepared using TRIzol LS Reagent (Invitrogen), according to the manufac-
turer’s protocols, followed by further purification with RNeasy (Qiagen) and DNase I treat-
ment. For 5′RACE, cDNA was synthesized with the SMART™ RACE cDNA Amplification Kit 
(Clontech) using ReverTra Ace (Toyobo) as a reverse transcriptase. For 3′RACE, the oligo(dT) 
primer 5′‐GACTCGAGTCGACATCGA(T)17‐3′ was used for cDNA synthesis.
Primer sets to amplify the partial coding region of each subunit (except sdhb2) were designed 
based on the TBLASTN search, which was performed against the database of E. multilocu‐
laris EST or genomic contig and shotgun reads [http://www.sanger.ac.uk/cgi‐bin/blast/sub-
mitblast/Echinococcus]. PCR was performed using Takara Ex Taq (Takara Bio) or PfuUltra II 
Fusion HS DNA polymerase (Stratagene). Gene‐specific primers for 5′RACE and 3′RACE were 
designed from determined sequences in the coding region. For sdhb2, gene‐specific primers 
were designed from the genomic contig (Table 1). All RACE experiments were performed as 
first PCR and nested PCR to obtain sufficient amplification of the DNA fragments. The uni-
versal primers for the first PCR and nested PCR for 5′RACE were universal primer mix and 
nested universal primers, respectively, which were provided within the SMART™ RACE 
cDNA Amplification Kit. For 3′RACE, the adaptor primer 5′‐GACTCGAGTCGACATCG‐3′ 
was used for both first and nested PCRs as the universal primer. These products were 
separated by electrophoresis on agarose gel, and target products were extracted with the 
MagExtractor‐PCR & Gel Clean up kit (Toyobo). The gel‐purified products were inserted 
into the pGEM‐T vector (Promega) after A‐tailing with Taq polymerase (Invitrogen) for 
sequencing. Entire ORFs were amplified using primers complementary to the determined 5′ 
UTR and 3′ UTR, and sequences were confirmed.
5.6. Enzyme inhibition assays
QFR and SQR assays were performed as described previously [36]. The final mitochondrial 
protein concentration was 50 μg/mL of the reaction mixture. QFR and SQR activities were 
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assayed under anaerobic and aerobic conditions, respectively. QFR and SQR activities were 
determined by monitoring the absorbance change of decyl RQ (60 μM) at 340 nm and ubi-
quinone‐2 (60 μM) at 278 nm (using SHIMADZU spectrophotometer UV‐3000), respectively. 
We determined IC50 values of the quinone‐binding site inhibitors against QFR activity of the mitochondria of protoscoleces. Flutolanil (Wako), atpenin A5 (ENZO Life Sciences), and 
ascofuranone were used in the assays (Figure 4). Ascofuranone was obtained from Align 
Pharmaceutical.
Figure 4. The chemical structure of inhibitors of the quinone‐binding site. A. Flutolanil, a competitive inhibitor of the 
quinone‐binding site of A. suum complex II. B. Atpenin A5, a competitive inhibitor of the quinone‐binding site of complex 
II of many species. C. Ascofuranone, a potent inhibitor of cyanide‐insensitive alternative oxidase of Trypanosoma brucei.
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